ACI's 4th Annual Biosimilars Forum
Download as PPTX, PDF0 likes744 views
ACI's 4th Annual Biosimilars program from June 5-7, 2013 provided the industry's leading legal and regulatory event on biosimilars. The agenda included insights from over 20 companies on branding and promotional considerations for biosimilars, as well as industry insights into when the first biosimilar applications would be submitted from over two dozen companies including Eli Lilly, AstraZeneca, Genentech and Pfizer. A keynote address was given by Denise Esposito from the FDA on regulatory policy issues.
1 of 1
Download to read offline
More Related Content
Similar to ACI's 4th Annual Biosimilars Forum (20)
Ad
More from Rachel Hamilton (20)
Ad
ACI's 4th Annual Biosimilars Forum
- 1. 1st 2nd 3rd 4th June 5-7, 2013 - AgendaTo learn more and register Click Here Drawing on 3 years of top-notch programming, ACI’s 4th Annual Biosimilars program remains the industry’s leading legal and regulatory event. FTC Spotlight: Addressing the Antitrust Concerns Resulting from Follow-On Legislation Suzanne Drennon Munck, Counsel for Intellectual Property, Federal Trade Commission. Insights from over 20 companies including a keynote address from Merck on Branding and Promotional Consideration for Biosimilars. Industry insights into when the first applications will be forthcoming from over two dozen companies including Eli Lilly, Astra Zeneca, Genentech, and Pfizer. Keynote Address from: Denise Esposito , Deputy Associate Director for Policy, Office of Regulatory Policy ( ORP), CDER Food & Drug Administration (FDA). AmericanConference.com/biosimilars
Editor's Notes
- #2: *